PubMed

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA.

Nat Med. 2009 Mar;15(3):285-92. Epub 2009 Feb 15.PMID: 19219022 [PubMed - indexed for MEDLINE]Related articlesFree article

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW.

Pharmacogenet Genomics. 2006 Nov;16(11):837-45.PMID: 17047492 [PubMed - indexed for MEDLINE]Related articles

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34.PMID: 16810109 [PubMed - indexed for MEDLINE]Related articles

"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.

Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

Structure. 2005 Dec;13(12):1887-95.PMID: 16338417 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.PMID: 16267764 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team.

Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.PMID: 16048984 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 15;41(2):236-42. Epub 2005 Jun 7.PMID: 15983922 [PubMed - indexed for MEDLINE]Related articles

Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Winters MA, Merigan TC.

Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. Review. No abstract available. PMID: 15980322 [PubMed - indexed for MEDLINE]Related articlesFree article

New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.

Winters MA, Kagan RM, Heseltine PN, Merigan TC.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):311-3.PMID: 15943574 [PubMed - indexed for MEDLINE]Related articles

Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.

Winters MA, Kagan RM, Kovari L, Heseltine PN, Merigan TC.

Antivir Ther. 2005;10(2):363-6.PMID: 15865232 [PubMed - indexed for MEDLINE]Related articles

Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.

Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):78-81.PMID: 15851917 [PubMed - indexed for MEDLINE]Related articles

Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.

Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, Merigan TC.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1166-72.PMID: 15588338 [PubMed - indexed for MEDLINE]Related articles

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW.

Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.PMID: 15561868 [PubMed - indexed for MEDLINE]Related articlesFree article

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.

Kagan RM, Merigan TC, Winters MA, Heseltine PN.

Antivir Ther. 2004 Oct;9(5):827-8. No abstract available. PMID: 15535422 [PubMed - indexed for MEDLINE]Related articles

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

J Virol. 2004 Mar;78(6):3123-32.PMID: 14990731 [PubMed - indexed for MEDLINE]Related articlesFree article

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC Jr, Glesby MJ; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

J Infect Dis. 2003 Dec 15;188(12):1804-14. Epub 2003 Dec 9.PMID: 14673758 [PubMed - indexed for MEDLINE]Related articles

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.PMID: 14668456 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2293-303.PMID: 14668455 [PubMed - indexed for MEDLINE]Related articlesFree article

Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group.

Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan TC Jr, Reichman RC, Berggren R, Burning WJ, Brobst S; Adult AIDS Clinical Trials Group 5096 Team.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):329-35.PMID: 12843743 [PubMed - indexed for MEDLINE]Related articles

HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization.

Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC.

Protein Expr Purif. 2003 Mar;28(1):165-72.PMID: 12651121 [PubMed - indexed for MEDLINE]Related articles

Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase.

Lobato RL, Kim EY, Kagan RM, Merigan TC.

AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):733-6.PMID: 12167282 [PubMed - indexed for MEDLINE]Related articles

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

AIDS. 2002 May 24;16(8):1131-8.PMID: 12004271 [PubMed - indexed for MEDLINE]Related articles

Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).

Kundu-Raychaudhuri S, Sevin A, Kilgo P, Nokta M, Pollard RB, Merigan TC.

AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1371-8.PMID: 11679149 [PubMed - indexed for MEDLINE]Related articles

Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

Kim EY, Winters MA, Kagan RM, Merigan TC.

J Virol. 2001 Nov;75(22):11227-33.PMID: 11602763 [PubMed - indexed for MEDLINE]Related articlesFree article

Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.

Winters MA, Merigan TC.

Antimicrob Agents Chemother. 2001 Aug;45(8):2276-9.PMID: 11451685 [PubMed - indexed for MEDLINE]Related articlesFree article

High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA.

J Clin Microbiol. 2001 Apr;39(4):1522-9.PMID: 11283081 [PubMed - indexed for MEDLINE]Related articlesFree article

Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.

Kim EY, Vrang L, Oberg B, Merigan TC.

AIDS Res Hum Retroviruses. 2001 Mar 20;17(5):401-7.PMID: 11282008 [PubMed - indexed for MEDLINE]Related articles

Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.

Winters MA, Coolley KL, Cheng P, Girard YA, Hamdan H, Kovari LC, Merigan TC.

J Virol. 2000 Nov;74(22):10707-13.PMID: 11044115 [PubMed - indexed for MEDLINE]Related articlesFree article

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC Jr, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M.

J Infect Dis. 2000 Nov;182(5):1357-64. Epub 2000 Oct 9.PMID: 11023459 [PubMed - indexed for MEDLINE]Related articles

Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.

Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1357-69.PMID: 11018855 [PubMed - indexed for MEDLINE]Related articles

In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients.

Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC.

Cell Transplant. 2000 May-Jun;9(3):307-17.PMID: 10972330 [PubMed - indexed for MEDLINE]Related articles

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.PMID: 10894268 [PubMed - indexed for MEDLINE]Related articles

Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.

Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC.

Antivir Ther. 2000 Mar;5(1):57-63.PMID: 10846594 [PubMed - indexed for MEDLINE]Related articles

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):341-7.PMID: 10634195 [PubMed - indexed for MEDLINE]Related articles

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B.

Ann Intern Med. 1999 Dec 7;131(11):813-21.PMID: 10610625 [PubMed - indexed for MEDLINE]Related articlesFree article

Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

Palmer S, Shafer RW, Merigan TC.

Antimicrob Agents Chemother. 1999 Aug;43(8):2046-50.PMID: 10428934 [PubMed - indexed for MEDLINE]Related articlesFree article

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.

Palmer S, Shafer RW, Merigan TC.

AIDS. 1999 Apr 16;13(6):661-7.PMID: 10397560 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW Jr, Merigan TC, Schroeder JS.

Circulation. 1999 Jul 6;100(1):61-6.PMID: 10393682 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC.

J Infect Dis. 1999 Jun;179(6):1356-64.PMID: 10228055 [PubMed - indexed for MEDLINE]Related articles

Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids.

Merigan TC.

J Reprod Immunol. 1998 Dec;41(1-2):177-85.PMID: 10213309 [PubMed - indexed for MEDLINE]Related articles

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.

Schapiro JM, Winters MA, Lawrence J, Merigan TC.

AIDS. 1999 Feb 25;13(3):359-65.PMID: 10199226 [PubMed - indexed for MEDLINE]Related articles

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK, Davis MM, Merigan TC.

J Immunol. 1999 Feb 1;162(3):1780-8.PMID: 9973442 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.

Kleim JP, Winters M, Dunkler A, Suarez JR, Riess G, Winkler I, Balzarini J, Oette D, Merigan TC.

J Infect Dis. 1999 Mar;179(3):709-13.PMID: 9952383 [PubMed - indexed for MEDLINE]Related articles

Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.

Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, Merigan TC.

AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1669-78.PMID: 9870321 [PubMed - indexed for MEDLINE]Related articles

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.

Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC.

J Infect Dis. 1999 Jan;179(1):249-53.PMID: 9841849 [PubMed - indexed for MEDLINE]Related articles

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC.

J Clin Invest. 1998 Nov 15;102(10):1769-75.PMID: 9819361 [PubMed - indexed for MEDLINE]Related articlesFree article

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.

Shafer RW, Winters MA, Palmer S, Merigan TC.

Ann Intern Med. 1998 Jun 1;128(11):906-11.PMID: 9634429 [PubMed - indexed for MEDLINE]Related articlesFree article

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.

Winters MA, Schapiro JM, Lawrence J, Merigan TC.

J Virol. 1998 Jun;72(6):5303-6.PMID: 9573309 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.

Gray CM, Schapiro JM, Winters MA, Merigan TC.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):561-9.PMID: 9591710 [PubMed - indexed for MEDLINE]Related articles

A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.

Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):551-60.PMID: 9591709 [PubMed - indexed for MEDLINE]Related articles